We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humana (HUM) Stock Slides as Market Rises: Facts to Know Before You Trade
Read MoreHide Full Article
Humana (HUM - Free Report) closed at $347.19 in the latest trading session, marking a -0.28% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.63%. Elsewhere, the Dow gained 0.2%, while the tech-heavy Nasdaq added 0.82%.
The the stock of health insurer has fallen by 5.12% in the past month, lagging the Medical sector's gain of 0.91% and the S&P 500's gain of 1.76%.
The investment community will be closely monitoring the performance of Humana in its forthcoming earnings report. The company is scheduled to release its earnings on April 24, 2024. The company's upcoming EPS is projected at $6.06, signifying a 35.39% drop compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $28.35 billion, up 6.01% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $16.05 per share and a revenue of $111.87 billion, representing changes of -38.48% and +7.84%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Humana. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.1% upward. Humana is currently sporting a Zacks Rank of #5 (Strong Sell).
In terms of valuation, Humana is presently being traded at a Forward P/E ratio of 21.69. For comparison, its industry has an average Forward P/E of 17.12, which means Humana is trading at a premium to the group.
It's also important to note that HUM currently trades at a PEG ratio of 2.04. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. HUM's industry had an average PEG ratio of 1.13 as of yesterday's close.
The Medical - HMOs industry is part of the Medical sector. This group has a Zacks Industry Rank of 194, putting it in the bottom 24% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Humana (HUM) Stock Slides as Market Rises: Facts to Know Before You Trade
Humana (HUM - Free Report) closed at $347.19 in the latest trading session, marking a -0.28% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.63%. Elsewhere, the Dow gained 0.2%, while the tech-heavy Nasdaq added 0.82%.
The the stock of health insurer has fallen by 5.12% in the past month, lagging the Medical sector's gain of 0.91% and the S&P 500's gain of 1.76%.
The investment community will be closely monitoring the performance of Humana in its forthcoming earnings report. The company is scheduled to release its earnings on April 24, 2024. The company's upcoming EPS is projected at $6.06, signifying a 35.39% drop compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $28.35 billion, up 6.01% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $16.05 per share and a revenue of $111.87 billion, representing changes of -38.48% and +7.84%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Humana. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.1% upward. Humana is currently sporting a Zacks Rank of #5 (Strong Sell).
In terms of valuation, Humana is presently being traded at a Forward P/E ratio of 21.69. For comparison, its industry has an average Forward P/E of 17.12, which means Humana is trading at a premium to the group.
It's also important to note that HUM currently trades at a PEG ratio of 2.04. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. HUM's industry had an average PEG ratio of 1.13 as of yesterday's close.
The Medical - HMOs industry is part of the Medical sector. This group has a Zacks Industry Rank of 194, putting it in the bottom 24% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.